These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 19106512)

  • 1. [The significance of combined treatment for hepatocellular carcinoma with partial splenic embolization and transcatheter arterial chemoembolization using IA call/lipiodol].
    Harao M; Beppu T; Masuda T; Hayashi H; Okabe H; Okabe K; Imseung C; Komori H; Horino K; Baba H
    Gan To Kagaku Ryoho; 2008 Nov; 35(12):2027-9. PubMed ID: 19106512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Study on primary hepatocellular carcinoma associated with hypersplenism treated by partial splenic embolization combined with hepatic arterial chemoembolization].
    Huang JH; Wu PH; Gu YK; Zhang FJ; Li CX; Gao F; Zhang L; Fan WJ; Li CJ
    Ai Zheng; 2006 Aug; 25(8):1003-6. PubMed ID: 16965683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Splenic embolization and hepatic chemoembolization: combined transcatheter treatment of hepatocellular carcinoma in cirrhosis with hypersplenism].
    Roversi R; Ricci S; Gambari PI; Castaldini L; Rossi G; Milandri G; Formica G; Dalmonte PR
    Radiol Med; 1993 Apr; 85(4):444-9. PubMed ID: 8390705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transarterial injection of (131)I-lipiodol, compared with chemoembolization, in the treatment of unresectable hepatocellular cancer.
    Marelli L; Shusang V; Buscombe JR; Cholongitas E; Stigliano R; Davies N; Tibballs J; Patch D; Meyer T; Burroughs AK
    J Nucl Med; 2009 Jun; 50(6):871-7. PubMed ID: 19443599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Partial splenic embolization for hypersplenism in cirrhosis: a long-term outcome in 62 patients.
    Zhu K; Meng X; Qian J; Huang M; Li Z; Guan S; Jiang Z; Shan H
    Dig Liver Dis; 2009 Jun; 41(6):411-6. PubMed ID: 19070555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Percutaneous treatment of hepatocellular carcinoma in patients with transjugular intrahepatic portosystemic shunts.
    Tesdal IK; Wikström M; Flechtenmacher C; Filser T; Dueber C
    Cardiovasc Intervent Radiol; 2006; 29(5):778-84. PubMed ID: 16779690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transarterial chemoembolization using degradable starch microspheres and iodized oil in the treatment of advanced hepatocellular carcinoma: evaluation of tumor response, toxicity, and survival.
    Kirchhoff TD; Bleck JS; Dettmer A; Chavan A; Rosenthal H; Merkesdal S; Frericks B; Zender L; Malek NP; Greten TF; Kubicka S; Manns MP; Galanski M
    Hepatobiliary Pancreat Dis Int; 2007 Jun; 6(3):259-66. PubMed ID: 17548248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined treatment of hepatocellular carcinoma with partial splenic embolization and transcatheter hepatic arterial chemoembolization.
    Huang JH; Gao F; Gu YK; Li WQ; Lu LW
    World J Gastroenterol; 2007 Dec; 13(48):6593-7. PubMed ID: 18161933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Efficacy and Safety of Partial Splenic Embolization in Hepatocellular Carcinoma Patients with Thrombocytopenia Who Underwent Transarterial Chemoembolization.
    Kim NH; Kim HJ; Cho YK; Hong HP; Kim BI
    J Korean Med Sci; 2019 Aug; 34(30):e208. PubMed ID: 31373186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of transcatheter arterial chemoembolization in the prevention of postoperative recurrence in 1630 patients with hepatocellular carcinoma].
    Cheng HY; Xu W; Xu AM; Chen D; Yang YF; Jia YC
    Zhonghua Zhong Liu Za Zhi; 2005 Oct; 27(10):626-8. PubMed ID: 16438876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant chemotherapy with tegafur/uracil administration after transcatheter arterial chemoembolization for advanced hepatocellular carcinoma.
    Ueda H; Tanaka H; Kida Y; Fukuchi H; Ichinose M
    Oncol Rep; 2008 May; 19(5):1355-61. PubMed ID: 18425398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of mesohepatectomy with or without transcatheter arterial chemoembolization for large centrally located hepatocellular carcinoma.
    Chen XP; Hu DY; Zhang ZW; Zhang BX; Chen YF; Zhang WG; Qiu FZ
    Dig Surg; 2007; 24(3):208-13. PubMed ID: 17522469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II trial of transcatheter arterial infusion chemotherapy with an epirubicin-Lipiodol emulsion for advanced hepatocellular carcinoma refractory to transcatheter arterial embolization.
    Tanaka T; Ikeda M; Okusaka T; Ueno H; Morizane C; Ogura T; Hagihara A; Iwasa S
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):683-8. PubMed ID: 17541589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead.
    Poon RT; Tso WK; Pang RW; Ng KK; Woo R; Tai KS; Fan ST
    Clin Gastroenterol Hepatol; 2007 Sep; 5(9):1100-8. PubMed ID: 17627902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Fédération Francophone de Cancérologie Digestive 9402).
    Doffoël M; Bonnetain F; Bouché O; Vetter D; Abergel A; Fratté S; Grangé JD; Stremsdoerfer N; Blanchi A; Bronowicki JP; Caroli-Bosc FX; Causse X; Masskouri F; Rougier P; Bedenne L;
    Eur J Cancer; 2008 Mar; 44(4):528-38. PubMed ID: 18242076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy and toxicity of transcatheter arterial chemoembolization with Cisplatin suspended in lipiodol for unresectable hepatocellular carcinoma].
    Uyama N; Hatano E; Maetani Y; Isoda H; Shibata T; Taura K; Oe S; Naito M; Yasuchika K; Fujii H; Ikai I; Uemoto S
    Gan To Kagaku Ryoho; 2008 May; 35(5):775-80. PubMed ID: 18487912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biliary phenotype of hepatocellular carcinoma after preoperative transcatheter arterial chemoembolization.
    Nishihara Y; Aishima S; Kuroda Y; Iguchi T; Taguchi K; Asayama Y; Taketomi A; Kinukawa N; Honda H; Tsuneyoshi M
    J Gastroenterol Hepatol; 2008 Dec; 23(12):1860-8. PubMed ID: 18823434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Laparoscopic splenectomy may be a superior supportive intervention for cirrhotic patients with hypersplenism.
    Tomikawa M; Akahoshi T; Sugimachi K; Ikeda Y; Yoshida K; Tanabe Y; Kawanaka H; Takenaka K; Hashizume M; Maehara Y
    J Gastroenterol Hepatol; 2010 Feb; 25(2):397-402. PubMed ID: 19929930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcatheter partial splenic arterial embolization in patients with hypersplenism: a clinical evaluation as supporting therapy for hepatocellular carcinoma and liver cirrhosis.
    Hirai K; Kawazoe Y; Yamashita K; Kumagai M; Tanaka M; Sakai T; Inoue R; Eguchi S; Majima Y; Abe M
    Hepatogastroenterology; 1986 Jun; 33(3):105-8. PubMed ID: 3017829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy for unresectable hepatocellular carcinoma may be improved by transcatheter arterial chemoembolization in combination with a traditional Chinese herbal medicine formula: a retrospective study.
    Yu Y; Lang Q; Chen Z; Li B; Yu C; Zhu D; Zhai X; Ling C
    Cancer; 2009 Nov; 115(22):5132-8. PubMed ID: 19672999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.